Patents by Inventor Sandeep Dutta
Sandeep Dutta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150196615Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: ApplicationFiled: March 27, 2015Publication date: July 16, 2015Applicant: AbbVie Inc.Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
-
Publication number: 20150164976Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection.Type: ApplicationFiled: February 23, 2015Publication date: June 18, 2015Applicant: AbbVie Inc.Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
-
Patent number: 8993578Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: December 23, 2013Date of Patent: March 31, 2015Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Patent number: 8969357Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.Type: GrantFiled: December 23, 2013Date of Patent: March 3, 2015Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Publication number: 20150024999Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.Type: ApplicationFiled: October 1, 2014Publication date: January 22, 2015Applicant: AbbVie Inc.Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
-
Publication number: 20150011481Abstract: The present invention features interferon-free therapies for treating HCV genotype 1b, 2, 3 or 4. In one aspect, the therapies comprise administering Compound 1, ritonavir, and Compound 2 to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include administration of any interferon, and the therapies last for 12 weeks. Preferably, the therapies do not include administration of any ribavirin.Type: ApplicationFiled: July 1, 2014Publication date: January 8, 2015Inventors: Regis A. Vilchez, Lino X. Rodrigues, JR., Barry M. Bernstein, Thomas J. Podsadecki, Scott C. Brun, Daniel E. Cohen, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Tolga Baykal
-
Publication number: 20140323395Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: ApplicationFiled: July 14, 2014Publication date: October 30, 2014Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Patent number: 8854355Abstract: An imaging system includes a detector configured to receive data that can be reconstructed into a three-dimensional (3D) image of an object, and a computer programmed to obtain 3D image data of the object, the 3D image data including an internal structure of the object, define a longitudinal dimension of the internal structure from the 3D image data along a length of the structure, extract a first set of parameter-of-interest data related to the internal structure from the 3D image data along a first ray extending from a first location along the length of the structure and at a first angular orientation with respect to a base vector that is generally perpendicular to the longitudinal dimension, and plot the extracted first set of parameter-of-interest data at a pixel location of a two-dimensional (2D) plot that corresponds to the first location and corresponds to the first angular orientation.Type: GrantFiled: December 11, 2009Date of Patent: October 7, 2014Assignee: General Electric CompanyInventors: John Skinner, Sandeep Dutta, Bernice E. Hoppel
-
Patent number: 8853176Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.Type: GrantFiled: October 19, 2012Date of Patent: October 7, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Publication number: 20140274934Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Barry M. Bernstein, Sandeep Dutta, Wei Liu, Thomas J. Podsadecki, Andrew L. Campbell, Rajeev M. Menon, Chih-Wei Lin, Tianli Wang, Walid M. Awni
-
Publication number: 20140275099Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Barry M. Bernstein, Sandeep Dutta, Wei Liu, Thomas J. Podsadecki, Andrew L. Campbell, Rajeev M. Menon, Chih-Wei Lin, Tianli Wang, Walid M. Awni
-
Patent number: 8809265Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Patent number: 8761479Abstract: A system and method for analyzing and visualizing spectral CT data includes access of a set of image data acquired from a patient comprising spectral CT data, identification of a plurality of target regions of interest (TROIs) and a reference region of interest (RROI) from the set of image data, extraction of a plurality of target spectral Hounsfield unit (HU) curves from image data representing the plurality of TROIs, extraction of a reference spectral HU curve from image data representing the RROI, normalization of the plurality of target spectral HU curves with respect to the reference spectral HU curve, and display of the plurality of normalized target spectral HU curves.Type: GrantFiled: November 8, 2010Date of Patent: June 24, 2014Assignee: General Electric CompanyInventors: Gopal Biligeri Avinash, Sandeep Dutta, Saad Ahmed Sirohey, Ananth P. Mohan
-
Publication number: 20140107017Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.Type: ApplicationFiled: December 23, 2013Publication date: April 17, 2014Applicant: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Publication number: 20140107016Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: ApplicationFiled: December 23, 2013Publication date: April 17, 2014Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Patent number: 8699812Abstract: A non-transitory computer readable storage medium having stored thereon a computer program comprising instructions, which when executed by a computer, cause the computer to acquire an image comprising image data reconstructed from an imaging device. The instructions further cause the computer to apply a bloom reduction algorithm to the image configured to iteratively reduce a blooming of high-density objects in the image.Type: GrantFiled: June 9, 2011Date of Patent: April 15, 2014Assignee: General Electric CompanyInventors: Jiang Hsieh, Sandeep Dutta
-
Patent number: 8685984Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: July 5, 2013Date of Patent: April 1, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Patent number: 8680106Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.Type: GrantFiled: July 5, 2013Date of Patent: March 25, 2014Assignee: AbbVic Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Patent number: 8680048Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: October 19, 2012Date of Patent: March 25, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Patent number: 8667192Abstract: An integrated circuit can include a processor system configured to execute program code. The processor system can be hard-wired and include a processor hardware resource. The IC also can include a programmable circuitry configurable to implement different physical circuits. The programmable circuitry can be coupled to the processor system. The programmable circuitry can be configurable to share usage of the processor hardware resource of the processor system. The processor system further can control aspects of the programmable circuitry such as power on and/or off and also configuration of the programmable circuitry to implement one or more different physical circuits therein.Type: GrantFiled: February 28, 2011Date of Patent: March 4, 2014Assignee: Xilinx, Inc.Inventors: William E. Allaire, Bradley L. Taylor, Ting Lu, Sandeep Dutta, Patrick J. Crotty, Hassan K. Bazargan, Hy V. Nguyen, Shashank Bhonge